Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Naud

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Vaccine|July 21, 2010
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult womenN De Carvalho, J Teixeira, C M Roteli-Martins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Clinical trials of cancer screening in the developing world and their impact on cancer healthcareR Sankaranarayanan, C Sauvaget, K Ramadas, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 3, 2006
Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of BrazilP Naud, J Matos, L Hammes, et al.
European Journal of Gynaecological Oncology|August 22, 2008
Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS studyA Longatto-Filho, C Roteli-Martins, L Hammes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 29, 2006
Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening studyA Longatto-Filho, M Erzen, M Branca, et al.
International Journal of STD & AIDS|May 17, 2008
Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohortK Syrjänen, P Naud, S Derchain, et al.
Journal of Lower Genital Tract Disease|October 18, 2006
Cervical cancer screening in Porto Alegre, Brazil: alternative methods for detecting cancer precursors in a developing countryP Naud, J Matos, L Hammes, et al.
International Journal of STD & AIDS|June 18, 2011
Risk estimates for persistent high-risk human papillomavirus infections as surrogate endpoints of progressive cervical disease critically depend on reference category: analysis of the combined prospective cohort of the New Independent States of the Former Soviet Union and Latin American Screening studiesK Syrjänen, I Shabalova, P Naud, et al.
Anticancer Research|August 17, 2005
Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS studyK Syrjänen, P Naud, S Derchain, et al.
European Journal of Gynaecological Oncology|October 25, 2012
Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the NIS-LAMS cohortK Syrjänen, I Shabalova, L Sarian, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Vaccine|July 21, 2010
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult womenN De Carvalho, J Teixeira, C M Roteli-Martins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Clinical trials of cancer screening in the developing world and their impact on cancer healthcareR Sankaranarayanan, C Sauvaget, K Ramadas, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 3, 2006
Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of BrazilP Naud, J Matos, L Hammes, et al.
European Journal of Gynaecological Oncology|August 22, 2008
Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS studyA Longatto-Filho, C Roteli-Martins, L Hammes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 29, 2006
Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening studyA Longatto-Filho, M Erzen, M Branca, et al.
International Journal of STD & AIDS|May 17, 2008
Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohortK Syrjänen, P Naud, S Derchain, et al.
Journal of Lower Genital Tract Disease|October 18, 2006
Cervical cancer screening in Porto Alegre, Brazil: alternative methods for detecting cancer precursors in a developing countryP Naud, J Matos, L Hammes, et al.
International Journal of STD & AIDS|June 18, 2011
Risk estimates for persistent high-risk human papillomavirus infections as surrogate endpoints of progressive cervical disease critically depend on reference category: analysis of the combined prospective cohort of the New Independent States of the Former Soviet Union and Latin American Screening studiesK Syrjänen, I Shabalova, P Naud, et al.
Anticancer Research|August 17, 2005
Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS studyK Syrjänen, P Naud, S Derchain, et al.
European Journal of Gynaecological Oncology|October 25, 2012
Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the NIS-LAMS cohortK Syrjänen, I Shabalova, L Sarian, et al.
Pageof 2